Rationale and Design for a Multicenter, Phase II Study of Durvalumab Plus Concurrent Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Study (WJOG11619L)
Motoko Tachihara(Kobe University), Kazuhiko Nakagawa(Osaka Red Cross Hospital), Nobuyuki Yamamoto(Wakayama Medical University), Miyako Satouchi(Memorial Sloan Kettering Cancer Center), Hidetoshi Hayashi(Kindai University), Koichi Azuma(Kyushu University Hospital), Kayoko Tsujino(Hyogo Prefectural Cancer Center), Takeshi Kodaira(Aichi Cancer Center), Shunsuke Teraoka(Wakayama Medical University), Takayasu Kurata(Kansai Medical University), Yuki Sato(Goethe University Frankfurt), Haruko Daga(Osaka City General Hospital), Shunichi Sugawara(Sendai Kousei Hospital), Takeaki Ishihara(Kobe University), Masafumi Yamaguchi(National Hospital Organization Kyushu Cancer Center), Isamu Okamoto(Kyushu University), Mototsugu Shimokawa(Yamaguchi University)
Cited by 8
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k